Update on the Pharmacological Actions of Enoxaparin in Nonsurgical Patients

TL;DR

This review summarizes the use of enoxaparin, a type of low-molecular-weight heparin, for preventing blood clots in patients who haven't had surgery.

Contribution

The paper compiles recent clinical experiences on enoxaparin's use in nonsurgical patients for VTE prevention.

Findings

Enoxaparin is effective in preventing venous thromboembolism in nonsurgical patients.

It has been used in various clinical settings beyond surgery, such as hemodialysis and recurrent abortion.

Evidence supports its role in treating acute coronary syndrome and preventing blood clots.

Abstract

Low-molecular-weight heparins are a class of drugs derived from the enzymatic depolymerization of unfractionated heparin that includes enoxaparin. Several studies have been performed on enoxaparin in recent years, in particular for the prevention and treatment of venous thromboembolism and for the treatment of acute coronary syndrome. Furthermore, the use of enoxaparin has been extended to other clinical situations that require antithrombotic pharmacological prevention, such as hemodialysis and recurrent abortion. In this review, we report the main clinical experiences of using enoxaparin in the prevention of VTE in nonsurgical patients.